The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

GSK GLAXOSMITHKLINE PLC ORD 25P




 Page 3 of 10

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Time/Date Code Headline Source Impact
15:33 01-Apr-2016 GSK Director/PDMR Shareholding RNS +2.42% Up
15:19 01-Apr-2016 GSK Director/PDMR Shareholding RNS +2.42% Up
15:07 01-Apr-2016 GSK GSK receives positive CHMP opinion for Strimvelis RNS +2.42% Up
13:01 01-Apr-2016 GSK Total Voting Rights RNS +2.42% Up
17:48 30-Mar-2016 GSK Director/PDMR Shareholding RNS +1.75% Up
12:00 30-Mar-2016 GSK Notice of AGM RNS +1.75% Up
17:23 29-Mar-2016 GSK Director/PDMR Shareholding RNS +1.24% Up
07:01 29-Mar-2016 GSK Marketing approval received for NucalaŽ in Japan RNS +1.24% Up
15:14 22-Mar-2016 GSK Director/PDMR Shareholding RNS -0.36% Down
16:09 21-Mar-2016 GSK Director/PDMR Shareholding RNS -0.90% Down
07:00 21-Mar-2016 GSK Annual Report 2015 on Form 20-F RNS -0.90% Down
14:58 18-Mar-2016 GSK Director/PDMR Shareholding RNS -1.18% Down
07:29 17-Mar-2016 GSK Vestri Study Results GSK Advair in Children 4-11 RNS -0.85% Down
07:00 17-Mar-2016 GSK Directorate Changes RNS -0.85% Down
07:00 17-Mar-2016 GSK Sir Andrew Witty to retire from GSK in March 2017 RNS -0.85% Down
07:00 17-Mar-2016 GSK Publication of 2015 Annual Financial Report RNS -0.85% Down
12:04 11-Mar-2016 GSK Director/PDMR Shareholding RNS +1.46% Up
14:40 10-Mar-2016 GSK Director/PDMR Shareholding RNS +1.50% Up
15:12 07-Mar-2016 GSK Director/PDMR Shareholding RNS +0.17% Up
07:00 07-Mar-2016 GSK NEJM results of LABA Safety Study of Advair Diskus RNS +0.17% Up

 Page 3 of 10

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address C8 Gsk House, 980 Great West Road, Brentford, TW8 9GS, United Kingdom
Company website http://www.gsk.com
Market cap(in millions)* £ 75,818.84
Listing/Admission to trading 22 May 1972
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
30-Jun-16
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 1,500
SEDOL 0925288
ISIN number GB0009252882


Start trading your favourite asset CFDs!
Carries risk of capital loss



GLAXOSMITHKLINE share news analysis (GSK)